Skip to Main Content

167

Views

0

CrossRef citations to date

0

Altmetric

Original Research

Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study

Jinjie Hea Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Weijuan Dub The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information

,

Haijing Yanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Jingjing Wanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Chenghang Caib The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information

,

Qingyang Mab The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information

,

Nanyang Lia Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Jicheng Yua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Xiaojie Wua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Jufang Wua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Yuancheng Chena Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information

,

Guoying Caoa Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaCorrespondence[email protected]
View further author information

&

Jing Zhanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaCorrespondence[email protected]
View further author information